Abstract 487P
Background
The United States Preventive Services Task Force (USPSTF) recommends low dose CT screening for lung cancer in individuals (1) 50-80 years old, (2) currently smoking or had quit for less than 15 years and (3) had at least a 20 pack-year smoking history. It is unclear if these guidelines will be applicable to our mixed Asian population. Our aim is to evaluate the performance of the USPSTF lung cancer screening criteria in our population of lung cancer patients.
Methods
We retrospectively reviewed the records of all asymptomatic patients who underwent resection of primary lung cancer in our institution between 2019 and 2021. Data collected included demographics, smoking status, histology and the final staging.
Results
We reviewed 259 consecutive cases of resectable primary lung cancer patients between 2019 and 2021. 145 patients were males (56.0%) and 114 patients were females (44.0%). There were 123 (47.5%) active or former smokers and 136 (52.5%) non-smokers. 83 patients (32.0%) met the USPSTF screening criteria and 176 patients (68.0%) did not. Lowering the age criteria to 45 years old increased the pickup rate to 34.4%. Male patients were more likely to meet the criteria (OR 2.27, 95% CI 1.87-2.76, p < 0.001) than female patients. The pickup rate increased significantly to 40.5% when patients who had stopped smoking for more than 15 years were included (p < 0.001) and 44.4% (p < 0.001) when patients who smoked less than 20 pack years were included. Screening by age criteria alone resulted in a pickup rate of 93.8% (males 94.5%, females 93.0%). Within this age range, the pickup rate in females was 84.2% in non-smokers and 8.8% in active or former smokers whilst the pickup rate in male was 22.1% in non-smokers and 72.4% in active or former smokers.
Conclusions
Our study showed the performance of the USPSTF criteria when applied to a mixed Asian population. It is concerning that more than two-thirds of patients will miss the opportunity for early curative resection if the guidelines were followed. A significant proportion of our patients were non-smokers, especially in the female population. A lung screening programme will need to be refined from existing guidelines to fit our local mixed Asian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract